Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Truly personalized therapy — an end to the era of one size fits all

In 2018, several trials in breast cancer have shown efficacy of strategies that rely on novel markers, including gene expression assays or pathological complete response. The relevance of targeted strategies in patient subgroups and of immunotherapy efficacy were demonstrated.

Key advances

  • Patients with node-negative luminal early stage breast cancer and a low or intermediate Oncotype DX recurrence score do not benefit from the addition of adjuvant chemotherapy to endocrine therapy1.

  • Patients with HER2-positive luminal early stage breast cancer and without a pathological complete response after neoadjuvant chemotherapy would benefit substantially from escalation of adjuvant therapy by switching to T-DM1 (ref.4).

  • Results on the efficacy of three cyclin-dependent kinase (CDK)4/6 inhibitors in all major phase III trials in patients with metastatic luminal breast cancer have now been presented, including one showing an overall survival (OS) benefit5,6,7.

  • In patients with PIK3CA-mutated metastatic breast cancer, alpelisib substantially improves progression-free survival (PFS) with a manageable toxicity profile8.

  • In patients with BRCA-mutated metastatic breast cancer, the addition of talazoparib to standard chemotherapy provided a PFS advantage over chemotherapy alone9.

  • In patients with triple-negative metastatic breast cancer, addition of atezolizumab to chemotherapy improved both PFS and OS; the strongest benefit was associated with expression of programmed cell death 1 ligand 1 (PD-L1)11.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111–121 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    Nitz, U. et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res. Treat. 165, 573–583 (2017).

    CAS  Article  Google Scholar 

  3. 3.

    Robertson, J. F. R. et al. Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer — the POETIC trial (CRUK/07/015). Cancer Res. 78(Suppl. 4), GS1-03 (2018).

    Article  Google Scholar 

  4. 4.

    von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. (2018).

    Article  Google Scholar 

  5. 5.

    Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465–2472 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 19, 904–915 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926–1936 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    André, F. et al. LBA3_PR. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase 3 SOLAR-1 trial. Ann. Oncol. 29 (Suppl. 8), mdy424.010 (2018).

    Google Scholar 

  9. 9.

    Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018).

    CAS  Article  Google Scholar 

  10. 10.

    Robson, M. E. et al. OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician’s choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Cancer Res. 78 (Suppl.), CT038 (2018).

    Article  Google Scholar 

  11. 11.

    Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Nadia Harbeck.

Ethics declarations

Competing interests

N.H. has received honoraria for lectures and/or consulting from Agendia, Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Nanostring, Novartis, Odonate, Pfizer, Roche, Sandoz–Hexal and Seattle Genetics. R.W. has received honoraria for lectures and/or consulting from Agendia, Amgen, AstraZeneca, Boeringer Ingelheim, Carl Zeiss, Celgene, Daiichi-Sankyo, Esai, Genomic Health, GlaxoSmithKline, Lilly, MSD, Nanostring, Novartis, Paxman, Palleos, Pfizer, Pierre Fabre, Puma Biotechnolgogy, Riemser, Roche, Sandoz–Hexal, Tesaro Bio and Teva.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Harbeck, N., Wuerstlein, R. Truly personalized therapy — an end to the era of one size fits all. Nat Rev Clin Oncol 16, 77–78 (2019).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing